Luke Sergott
Stock Analyst at Barclays
(2.09)
# 2,612
Out of 4,670 analysts
238
Total ratings
37.78%
Success rate
-6.09%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Overweight | $55 → $52 | $42.23 | +23.14% | 16 | Nov 19, 2024 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $20 → $25 | $19.73 | +26.71% | 7 | Nov 11, 2024 | |
| CERT Certara | Maintains: Equal-Weight | $14 → $12 | $10.36 | +15.83% | 14 | Nov 7, 2024 | |
| ILMN Illumina | Maintains: Equal-Weight | $135 → $145 | $140.14 | +3.47% | 14 | Nov 5, 2024 | |
| WAT Waters | Maintains: Underweight | $330 → $360 | $373.47 | -3.61% | 16 | Nov 4, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $260 → $255 | $201.82 | +26.35% | 19 | Nov 1, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $21 → $19 | $14.31 | +32.77% | 8 | Nov 1, 2024 | |
| AVTR Avantor | Maintains: Overweight | $28 → $25 | $20.78 | +20.31% | 20 | Oct 25, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $330 → $275 | $214.25 | +28.35% | 16 | Oct 25, 2024 | |
| TMO Thermo Fisher | Maintains: Equal-Weight | $620 → $610 | $513.26 | +18.85% | 23 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $285 → $275 | $235.84 | +16.60% | 36 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $135 → $145 | $133.84 | +8.34% | 5 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $125 → $140 | $112.03 | +24.97% | 6 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $210 | $195.77 | +7.27% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $12.82 | +32.61% | 16 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $47 → $63 | $60.98 | +3.31% | 16 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.80 | +11.11% | 4 | May 10, 2024 |
Twist Bioscience
Nov 19, 2024
Maintains: Overweight
Price Target: $55 → $52
Current: $42.23
Upside: +23.14%
Fortrea Holdings
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $19.73
Upside: +26.71%
Certara
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $14 → $12
Current: $10.36
Upside: +15.83%
Illumina
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $135 → $145
Current: $140.14
Upside: +3.47%
Waters
Nov 4, 2024
Maintains: Underweight
Price Target: $330 → $360
Current: $373.47
Upside: -3.61%
IQVIA Holdings
Nov 1, 2024
Maintains: Overweight
Price Target: $260 → $255
Current: $201.82
Upside: +26.35%
10x Genomics
Nov 1, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $14.31
Upside: +32.77%
Avantor
Oct 25, 2024
Maintains: Overweight
Price Target: $28 → $25
Current: $20.78
Upside: +20.31%
ICON Public Limited Company
Oct 25, 2024
Maintains: Overweight
Price Target: $330 → $275
Current: $214.25
Upside: +28.35%
Thermo Fisher
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $620 → $610
Current: $513.26
Upside: +18.85%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $285 → $275
Current: $235.84
Upside: +16.60%
Oct 15, 2024
Maintains: Underweight
Price Target: $135 → $145
Current: $133.84
Upside: +8.34%
Oct 15, 2024
Upgrades: Overweight
Price Target: $125 → $140
Current: $112.03
Upside: +24.97%
Aug 8, 2024
Maintains: Equal-Weight
Price Target: $230 → $210
Current: $195.77
Upside: +7.27%
Aug 6, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $12.82
Upside: +32.61%
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $47 → $63
Current: $60.98
Upside: +3.31%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.80
Upside: +11.11%